World Cancer Day 2026 – united by unique: Cell lines for national and international cancer research – Leibniz Institute DSMZ cell line collection ...

Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by ...

Novel therapies targeting molecular pathways, including DLL3 and PARP inhibitors, show promise in improving SCLC survival outcomes. Tarlatamab, a DLL3-targeting bispecific T-cell engager, achieved a ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

Circulating tumor DNA may be an effective biomarker for stratifying patients with small cell lung cancer who would benefit from more stringent follow-ups and clinical trial participation.Patients who ...

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer. During the CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...